Diphenoxylate HCl/Atropine Sulfate Oral Solution CV
Generic Name and Formulations:
Diphenoxylate HCl 2.5mg, atropine sulfate 0.025mg; per 5mL liq; alcohol 15%.
West-Ward Pharmaceutical Corp.
Indications for Diphenoxylate HCl/Atropine Sulfate Oral Solution:
Adjunct therapy in the management of diarrhea.
10mL 4 times daily until diarrhea is controlled; max 20mg/day. Maintenance: 10mL daily. Discontinue if no improvement within 10 days after treatment with max dose.
See full labeling. <2yrs: not recommended. 2–12yrs: initially 0.3–0.4mg/kg in 4 divided doses until diarrhea is controlled. Maintenance: 25% of initial dose; max 48hrs.
Obstructive jaundice. Diarrhea associated with pseudomembranous enterocolitis or other enterotoxin-producing bacteria.
Dehydration. Electrolyte imbalance. Acute ulcerative colitis; discontinue if toxic megacolon occurs. Hepatic or renal impairment. Drug abusers. Pregnancy (Cat.C). Nursing mothers.
Opioid + anticholinergic.
Concomitant MAOIs may cause hypertensive crisis; avoid use. Potentiates sedation with alcohol, CNS depressants (eg, barbiturates, tranquilizers). May delay elimination of other drugs metabolized by CPY450.
Nausea, vomiting, abdominal discomfort, paralytic ileus, toxic megacolon, dizziness, drowsiness, headache, euphoria, tachycardia, numbness of extremities, pruritus, urticaria, angioneurotic edema, anticholinergic effects; respiratory depression (overdosage), atropinism (esp in pediatrics with Down's syndrome).
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|